1 / 24

Practical Considerations in Clinical Management

Practical Considerations in Clinical Management. Guideline-recommended glycemic targets in diabetes. *Plasma; † Blood ADA = American Diabetes Association ACE = American College of Endocrinology. ADA. Diabetes Care . 2007;30(suppl 1):S4-41. ACE. Endocr Pract . 2002;8(suppl 1):5-11.

jackg
Download Presentation

Practical Considerations in Clinical Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Practical Considerations in Clinical Management

  2. Guideline-recommended glycemic targets in diabetes *Plasma; †Blood ADA = American Diabetes AssociationACE = American College of Endocrinology ADA. Diabetes Care. 2007;30(suppl 1):S4-41. ACE. Endocr Pract. 2002;8(suppl 1):5-11.

  3. Glucose dynamics: Basal and prandial 250 Postprandial hyperglycemia 200 Type 2diabetes Plasma glucose (mg/dL) 150 Basal hyperglycemia 100 50 Normal 0 0600 1200 1800 2400 0600 Time of day Riddle MC. Am J Med. 2004;116(suppl):3S-9.

  4. Relative contributions of postprandial glucose and FPG to A1C 100 80 60 Contribution (%) 40 20 0 <7.3 7.3–8.4 8.5–9.2 9.3–10.2 >10.2 A1C quintiles (%) Fasting plasma glucose Postprandial plasma glucose Monnier L et al. Diabetes Care. 2003;26:881-5.

  5. Glycemic control deteriorates with standard therapies N = 2220 with T2DM treated with SU + MET Pre-SU A1C levels (%) 100 ≥10 9.0-9.9 8.0-8.9 4.0-7.9 80 Patients withA1C ≥8% (%) 60 • ~85% of patients had A1C ≥8% after 4 years 40 20 0 0 1 2 3 4 Time from sulfonylurea initiation (years) SU = sulfonylurea, MET = metformin Cook MN et al. Diabetes Care. 2005;28:995-1000.

  6. A1C reduction with glucose-lowering medications *Monotherapy DPP = dipeptidyl peptidase; GLP = glucagon-like peptide Nathan DM. N Engl J Med. 2007;356:437-40.

  7. Oral diabetes agents Trujillo J. Formulary. 2006. Luna B, Feinglos MN. Am Fam Physician. 2001. Smyth S, Heron A. Nat Med. 2006.

  8. Incretin agents in glucose control GIP = gastric inhibitory peptide Trujillo J. Formulary. 2006;41:130-41.

  9. ADA: Managing hyperglycemia in T2DM Lifestyle intervention + metformin If A1C > goal Add basal insulin(most effective) Add sulfonylurea(least expensive) Add glitazone(no hypoglycemia) If A1C > goal If A1C > goal If A1C > goal Intensify insulin Add glitazone Add basal insulin Add sulfonylurea If A1C > goal If A1C > goal Add basal or intensify insulin Intensive insulin + metformin +/- glitazone ADA goal: A1C <7% Adapted from ADA. Diabetes Care. 2007;30(Suppl 1):S4-41.

  10. ACE road map to glycemic goals in T2DM: Treated patients A1C (%) Current therapy Intervention Mono- or combination therapy Initiate insulin therapy (basal-bolus) >8.5 • Monitor every2–3 months • Adjust treatment to meet ACE glycemic goals Combination therapy Maximize OAD combinations Maximize insulin therapy 6.5–8.5 Continue lifestyle modification Monotherapy Initiate combination therapy* Mono- or combination therapy Continue therapy oradjust as needed to meet ACE glycemic targets 6.0–6.5 *Add rapid-acting insulin analogs at any time to address persistent postprandial hyperglycemia ACE/AACE. www.aace.com.

  11. Treat-to-Target study: Basal insulin lowers FPG and A1C N = 756 previously treated with 1–2 OADs; Mean A1C 8.6% 9 200 8 FPG, mean(mg/dL) A1C,mean (%) 150 7 6 100 0 4 8 12 16 20 24 0 4 8 12 16 20 24 Weeks of treatment ~60% reached A1C ≤7% Insulin glargine NPH NPH = neutral protamine Hagedorn insulin Riddle MC et al. Diabetes Care. 2003;26:3080−6.

  12. Treat-to-Target: Nocturnal hypoglycemia vs glycemic control Riddle MC et al. Diabetes Care. 2003;26:3080―6.

  13. Fewer hypoglycemic episodes withinsulin analogue N = 371 with poorly controlled T2DM on SU + MET P < 0.0001 Hypoglycemic events, mean(per patient-years) P = 0.0009 P = 0.0449 Insulin glargine + OAD Premixed insulin* *30% regular/70% NPH insulin Janka HU et al. Diabetes Care. 2005;28:254-9.

  14. Insulin glargine + OAD effect on weight, A1C N = 12,216 with poorly controlled T2DM on OAD; 9-month outcomes BMI subgroup analysis  BMI (kg/m2) BMI (kg/m2) <25 25 to <30 30 to <35 ≥35 All A1C (%) -1.6 -1.6 -1.7 -1.8 -1.6  = change from baseline at 9 months Schrieber SA, Haak T. Diabetes Obes Metab. 2007;9:31-8.

  15. Glycemic control and weight change with detemir vs NPH insulin N = 475 with poorly controlled T2DM on OAD; add-on detemir or NPH 10 189 187 9 185 8 Body weight (lbs) A1C (%) 182 7 180 6 178 0 0 -2 0 4 8 12 16 20 24 -2 0 4 8 12 16 20 24 Study week Study week >70% achieved A1C ≤7% Mean weight gain (lbs) Detemir: 2.6; NPH: 6.2 (P < 0.001) Detemir NPH Hermansen K et al. Diabetes Care. 2006;29:1269-74.

  16. Add-on treatment with glargine vs rosiglitazone + SU/MET: A1C and FPG N = 217 with T2DM 7 8 9 10 11 0 200 -0.5 180 -1.0 † A1C,  from baseline(%) 160 † FPG, mean (mg/dL) -1.5 * * † -2.0 * † 140 * -2.5 120 -3.0 -3.5 100 0 4 8 12 16 20 24 Time (weeks) Insulin glargine Rosiglitazone *P < 0.05, †P = 0.001 between groups Rosenstock J et al. Diabetes Care. 2006;29:554-9.

  17. Glargine vs rosiglitazone added to SU + MET: Lipid effects N = 217 with T2DM HDL-C Total-C LDL-C TG 20 † 13.1 * 10.1 10 ‡ § 4.6 4.4 Change from baseline (%) 0 0 -1.4 -4.4 -10 -20 -19.0 Insulin glargine Rosiglitazone *P = 0.0001, †P = 0.0004, ‡P = 0.001, §P = 0.04 between groups Rosenstock J et al. Diabetes Care. 2006;29:554-9.

  18. Add-on Rx with glargine vs rosiglitazone + SU/MET: Comparative adverse effects N = 217 with T2DM *Plasma glucose <70 mg/dL Rosenstock J et al. Diabetes Care. 2006;29:554-9.

  19. Basal and bolus insulin pharmacodynamics Basal Bolus RHI = regular human insulin Flood TM. J Fam Practice. 2007;56(suppl):S1-12.

  20. Traditional thinking Atherogenic Fear of hypoglycemia Fear of weight gain Frequent injections Newer concepts Anti-atherogenic Less nocturnal hypoglycemia with steady-state once-daily basal insulins Weight neutral Long-acting basal insulins require fewer injections Dispelling misconceptions about insulin Dandona P et al. Am J Cardiol. 2007;99(suppl):15B-26. Stotland NL. Insulin. 2006;1:38-45.

  21. ACC/AHA secondary prevention guidelines: Diabetes management Class and level of evidence I IIa IIb III Initiate lifestyle and pharmacotherapy to achieve A1C <7% B Aggressively modify other CV risk factors (physical activity, weight, BP, cholesterol) B C Coordinate care with endocrinologist or PCP Smith SC et al. Circulation. 2006;113:2363-72.

  22. Discharge strategies for patients with hyperglycemia Lifestyle modification (nutrition and exercise) Insulin vs OAD for long-term management Patient educationeg, self-monitoring of glucose Continuity of carePCP ± Endocrinologist ACE/ADA. Diabetes Care. 2006;29:1955-62.

  23. Managing glucose in T2DM • Diabetes is a progressive disease • Most patients will require multiple therapies to achieve A1C goals • Utilize lifestyle intervention and metformin as initial treatment • Add medications rapidly and transition to new agents when A1C target is not achieved/sustained • Add insulin early in patients who do not meet A1C targets Nathan DM et al. Diabetologia. 2006;49:1711-21.

  24. Continuity of care for diabetes: It takes a health care team Patient Physician Diabeteseducator Eye doctor Dietician Exercise physiologist Podiatrist Social worker or psychologist ADA. www.diabetes.org.

More Related